Cell-based therapies go live

Nature Biotechnology

Volumn 20, Issue 4, 2002, Pages 339-343

  Dove, Alan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MATERIALS; DISEASE CONTROL;

CELL BASED THERAPY;

CELLS;

ADOPTIVE IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL REGENERATION; CELL TRANSPLANTATION; DRUG DELIVERY SYSTEM; HUMAN; INDUSTRY; KILLER CELL; LAW; MEDICAL ETHICS; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0036218797     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0402-339     Document Type: Review

References (11)

1. The status of high-dose chemotherapy in breast cancer
2. Cell factories for fighting cancer
3. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol
4. Immunotherapy with dendritic cells directed against tumour antigens shared with normal host cells results in severe autoimmune disease
5. Efficient generation of human T cells from a tissue-engineered thymic organoid
6. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB
7. Regenerative medicine
8. Six-year clinical effect of donor bone marrow infusions in renal transplant patients
9. Hematopoietic colony-forming cells derived from human embryonic stem cells
10. US deliberate on embryonic stem cells, cloning
11. US stem cell policy comes under fire